Posted by Michael Wonder on 05 Dec 2017
Health Canada approves Rydapt (midostaurin), first targeted therapy for common form of acute myeloid leukaemia
5 December 2017 - Targeted therapy treats most common gene mutation (FLT3) found in more than one third of AML patients.
Novartis Pharmaceuticals Canada is pleased to announce that Rydapt (midostaurin), the first targeted therapy for FLT3 mutated acute myeloid leukaemia has been approved following a priority review by Health Canada.
Health Canada approval of Rydapt is based on the pivotal phase III study (RATIFY) which investigated the efficacy and safety of Rydapt in combination with standard chemotherapy versus placebo plus standard chemotherapy.
